August 7, 2012Antioxidants and Redox Signaling
Angiogenesis in the Infarcted Myocardium
View Full Paper
Ask AI
Bookmark
Share
Key result
Proangiogenic therapies for acute myocardial infarction have shown mixed clinical results, suggesting that delivery of a single growth factor or cell type does not sufficiently support cardiac repair.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Single-factor proangiogenic therapies remain inadequate for AMI repair; leaves open combined targeting of angiogenesis plus vessel maturation.
PICO
P
Population
Myocardial Infarction
I
Intervention / Comparator
Proangiogenic therapy
Future proangiogenic therapies for myocardial infarction must target both angiogenesis and vessel maturation, and consider the complex cross-talk between endothelial cells and cardiomyocytes.
Limitations
- Methodological caveats such as delivery methods for angiogenic growth factors and isolation procedures for regenerative cells might partially explain the failure of clinical trials.
- Cardiovascular risk factors such as hypertension, diabetes, or hyperlipidemia profoundly impair endogenous and therapeutically induced post-MI angiogenesis.
Cite This Study
Cochain et al. (2012) conducted a review in Myocardial Infarction. Proangiogenic therapy was evaluated. Proangiogenic therapies for acute myocardial infarction have shown mixed clinical results, suggesting that delivery of a single growth factor or cell type does not sufficiently support cardiac repair.
View Full Paper
Ask AI
Bookmark
Share